Skip to content

Michael Bloomfield

17 papers in the library · 2,793 citations · publishing 2012-2025

Papers

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Lancet Psychiatry May 17, 2016 Robin L Carhart-Harris, Mark Bolstridge, James Rucker et al. 1,546 citations

In an open-label trial, 12 patients with moderate-to-severe treatment-resistant depression received two doses of psilocybin (10 mg and 25 mg, one week apart) in a supportive setting. The psychedelic effects peaked 2-3 hours after dosing and subsided within 6 hours. No serious adverse events occurred; transient anxiety, confusion, nausea, and headache were noted. Depressive symptoms, measured with the Quick Inventory of Depressive Symptoms, were markedly reduced one week after the high dose (mean reduction of 11.8 points) and remained lower at three months (mean reduction of 9.2 points). Improvements in anxiety and anhedonia were also observed. The results provide preliminary support for psilocybin's safety and efficacy in treatment-resistant depression, warranting further controlled trials.

The neuropsychopharmacology of cannabis: A review of human imaging studies

Pharmacology & Therapeutics October 20, 2018 Michael Bloomfield, Chandni Hindocha, Sebastian F Green et al. 236 citations

Cannabis and its primary psychoactive component, THC, acutely alter executive, emotional, reward, and memory processing by directly interacting with the endocannabinoid system and indirectly affecting glutamatergic, GABAergic, and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid, may offset some of these acute effects. Heavy repeated cannabis use, especially during adolescence, is associated with adverse effects that increase the risk of mental illnesses such as addiction and psychosis. This review synthesizes human neuroimaging research on the acute and chronic neuropsychopharmacology of cannabis, covering effects during development, implications for psychosis and cannabis use disorder, and methodological considerations.

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity

Biological Psychiatry January 10, 2014 Robin Carhart‐Harris, Kevin Murphy, Robert Leech et al. 182 citations

The medial temporal lobes (MTLs) are specifically involved in how MDMA works in the brain, though more research is needed to understand how the drug's characteristic subjective effects emerge from its modulation of spontaneous brain activity.

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses

Psychopharmacology September 2, 2016 Will Lawn, Tom P. Freeman, Rebecca Pope et al. 177 citations

Cannabis containing only THC reduced the likelihood of choosing high-effort rewards compared to placebo, indicating a transient amotivational state, while adding CBD altered the effect of THC on expected value. Cannabis-dependent individuals showed preserved motivation but impaired reward learning compared to non-dependent controls, though depression may have influenced results.

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

Three weekly infusions of ketamine (0.8 mg/kg) helped people with severe alcohol use disorder stay abstinent more days over six months than placebo infusions did. The ketamine group averaged 10.1% more days abstinent than the placebo group. Combining ketamine with mindfulness-based relapse prevention therapy produced the largest improvement, with 15.9% more abstinent days compared with placebo plus alcohol education. No serious adverse events occurred. Relapse rates did not differ significantly between ketamine and placebo groups. The findings suggest ketamine is safe and may support abstinence, especially when paired with psychological therapy.

The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories

The International Journal of Neuropsychopharmacology December 17, 2013 Robin Carhart‐Harris, Matthew B. Wall, David Erritzøe et al. 110 citations

MDMA (ecstasy) makes recalling favorite autobiographical memories feel more vivid, emotionally intense, and positive, while making recall of worst memories feel less negative. In a double-blind, placebo-controlled fMRI study with 19 participants who had prior MDMA experience, 100 mg of MDMA altered brain activity during memory recall: it increased activation in the fusiform gyrus and somatosensory cortex for favorite memories and decreased activation in the left anterior temporal cortex for worst memories. These neural changes suggest MDMA creates a positive emotional bias, which may explain why it helps patients revisit traumatic memories during psychotherapy for PTSD.

Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Schizophr Bull January 26, 2012 Oliver D. Howes, Paul Shotbolt, Michael Bloomfield et al. 94 citations

Auditory hallucinations in healthy individuals are associated with altered dopamine function in the brain. Using [18F]-DOPA PET imaging, the study found that healthy people who experience auditory hallucinations show differences in dopaminergic activity compared to those who do not, suggesting that dopamine dysfunction may be a trait marker along the psychosis spectrum. The findings indicate that even in the absence of a clinical diagnosis, hallucination proneness is linked to measurable neurochemical variations.

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity

Journal of Psychopharmacology April 23, 2019 Matthew B. Wall, Rebecca Pope, Tom P. Freeman et al. 89 citations

Two strains of cannabis—one containing only THC (8 mg) and another containing THC plus CBD (8 mg THC + 10 mg CBD)—were compared with placebo in seventeen healthy, experienced but non-regular cannabis users. Using resting-state fMRI, both strains reduced functional connectivity in the default mode and salience networks relative to placebo, but with distinct spatial patterns. The THC-only strain specifically disrupted the posterior cingulate cortex within the default mode network, and this disruption correlated with subjective feelings of being 'stoned' and 'high'. The THC-plus-CBD strain produced less disruption of the salience network, suggesting CBD may buffer THC's effects on salience processing, which could underlie its potential therapeutic role in disorders like psychosis and addiction.

Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion

The International Journal of Neuropsychopharmacology August 30, 2017 Tom P. Freeman, Rebecca Pope, Matthew B. Wall et al. 67 citations

Cannabis dampens the brain's response to music in regions involved in reward and emotion, including the auditory cortex, hippocampus, amygdala, and ventral striatum. However, when cannabis also contains cannabidiol, these dampening effects are offset, and brain activity does not differ from placebo. Despite reduced neural responses, both types of cannabis increased participants' self-reported desire to listen to music and enhanced sound perception. The findings suggest that cannabidiol may mitigate some of cannabis's effects on brain reward systems.

The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment

Addiction February 8, 2023 Will Lawn, Katie Trinci, Claire Mokrysz et al. 36 citations

Adolescent cannabis users are neither more resilient nor more vulnerable than adult cannabis users to the acute psychotomimetic, verbal memory-impairing, or subjective effects of cannabis. In a randomized, double-blind, placebo-controlled crossover experiment with 24 adolescents (16-17 years old) and 24 adults (26-29 years old) who used cannabis 0.5-3 days per week, vaporized THC (8 mg for a 75 kg person) and THC plus CBD (24 mg) both significantly increased subjective drug effect, impaired verbal episodic memory, and increased psychotomimetic effects compared to placebo. There was no evidence that adolescents differed from adults in their responses, and CBD did not modulate the acute effects of THC.

Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence

Psychological Medicine April 28, 2020 Claire Mokrysz, Natacha D. C. Shaban, Tom P. Freeman et al. 24 citations

Inhaling cannabis reliably increases psychotic-like symptoms in healthy cannabis users and may raise the incidence of speech illusion—hearing words in meaningless white noise. Cannabidiol (CBD) did not blunt these effects. In one study, adults had stronger psychotic-like symptom responses than adolescents, suggesting adolescents may be less vulnerable to the acute psychotic-like effects of cannabis. The odds of experiencing speech illusion were 3.1 times higher after inhaling cannabis with THC and negligible CBD compared to placebo.

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Journal of Psychopharmacology August 5, 2020 Will Lawn, J. P. Hill, Chandni Hindocha et al. 23 citations

A single 600 mg oral dose of cannabidiol did not alter brain activity related to anticipating or receiving rewards in healthy adults. Using functional magnetic resonance imaging during a monetary incentive delay task, the expected reward-related brain regions—including the insula, caudate, nucleus accumbens, anterior cingulate, and orbitofrontal cortex—were activated, but no difference was observed between cannabidiol and placebo. Bayesian analyses confirmed that activity in these regions was similar under both conditions, and behavioral measures of motivation for reward also showed no significant difference. The findings suggest that acute cannabidiol does not affect the neural correlates of reward anticipation or feedback in healthy individuals.

Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain

Journal of Psychopharmacology May 20, 2022 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 21 citations

THC strongly disrupts connectivity between the striatum and cortex, but co-administering CBD mitigates this effect in the limbic striatum network. In one study, inhaled cannabis with 8 mg THC or 8 mg THC plus 10 mg CBD disrupted associative and sensorimotor networks, while THC alone also disrupted the limbic striatum network. In a second study, oral 600 mg CBD increased connectivity in the associative network and caused minor disruptions in limbic and sensorimotor networks. The insula emerges as a key region affected by cannabinoid-induced changes in functional connectivity, with implications for understanding cannabis-related disorders and developing cannabinoid therapeutics.

The experience and role of dissociation in psychosis following developmental trauma: A systematic review

Clinical Psychology Review February 26, 2025 Eirini Aikaterini Melegkovits, Rui Tang, Olivia Pounds et al. 8 citations

A systematic review of 40 studies with 6941 participants found a moderate association between developmental trauma (abuse or neglect before age 18) and dissociation in people with psychosis. Sexual and emotional abuse showed the strongest links to dissociation. Dissociation partially explained the connection between developmental trauma and positive psychotic symptoms, especially hallucinations, and also contributed to paranoia and delusional ideas. Individuals with psychosis and developmental trauma reported more dissociation than those without trauma. The review recommends screening for psychotic and dissociative symptoms in trauma survivors and managing dissociation, while calling for more longitudinal, qualitative, and experimental research.

The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study

Psychopharmacology February 28, 2024 Daniel L. Hall, Will Lawn, Shelan Ofori et al. 5 citations

Acute intoxication with vaporized THC eliminated attentional bias away from cannabis-related cues in both adolescents and adults who used cannabis 0.5–3 days per week. In a randomized, double-blind, placebo-controlled crossover study with 48 participants (24 adolescents aged 16–17 and 24 adults aged 26–29), a weight-adjusted dose of 8 mg THC eliminated the bias, while adding 24 mg CBD did not alter this effect. There was no significant difference in response between age groups. The findings suggest that acute THC intoxication shifts attentional processing of cannabis cues, but CBD does not moderate this effect.

Individual and combined effects of Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) on striato-cortical connectivity in the human brain

bioRxiv (Cold Spring Harbor Laboratory) November 21, 2020 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 4 citations preprint

Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are two major cannabis constituents with contrasting actions: THC is psychoactive and addiction-promoting, while CBD may have opposite effects. In two placebo-controlled, double-blind studies, inhaled THC (8 mg) strongly disrupted functional connectivity in associative and sensorimotor striatal networks, and this disruption was selectively alleviated in the limbic striatum when co-administered with CBD (10 mg). Oral CBD (600 mg) alone increased connectivity in the associative network but caused minor decreases in limbic and sensorimotor networks. The insula emerged as a key region affected by cannabinoid-induced connectivity changes, with implications for cannabis-related disorders and cannabinoid therapeutics.

Dissociative experiences in individuals with subclinical psychosis and a history of developmental trauma: a qualitative study.

European journal of psychotraumatology December 1, 2025 Eirini Aikaterini Melegkovits, Ava Mason, Jordan Reid et al. 2 citations

Among people with subclinical psychosis who have a history of developmental trauma, dissociative experiences are common, confusing, and often distressing. These experiences involve detachment and compartmentalization and are linked to emotions, past trauma, and psychotic-like phenomena. The findings underscore the need for better clinical recognition and tailored interventions for this group.